Reviving the acid phosphatase test for prostate cancer

ONCOLOGY

Volumn 21, Issue 8, 2007, Pages 1003-1010

  Taira, Al ^a   Merrick, Gregory ^b   Wallner, Kent ^c   Dattoli, Michael ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Brachytherapy Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

ACID PHOSPHATASE BLOOD LEVEL; ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; ENZYME ANALYSIS; HIGH RISK PATIENT; HUMAN; PROSTATE CANCER; REVIEW;

HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; TUMOR MARKERS, BIOLOGICAL;

EID: 34547104815     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Lu-Yao GL, Potosky AL, Albertsen PC, et al: Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. J Natl Cancer Inst 88:166-173, 1996.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
3. Pienta KJ, Smith DC: Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 55:300-318, 2005.
4. Copp H, Bissonette EA, Theodorescu D: Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology 65:1146-1151, 2005.
5. Stock RG, Ho A, Cesaretti JA, et al: Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66:389-394, 2006.
6. Romas NA: Prostatic acid phosphatase: Current concepts. Semin Urol 1:177-185, 1983.
7. Foti AG, Herschman H, Cooper JF: Comparison of human prostatic acid phosphatase by measurement of enzymatic activity and by radioimmunoassay. Clin Chem 23:95-99, 1977.
8. Heller JE: Prostatic acid phosphatase: Its current clinical status. J Urol 137:1091-1103, 1987.
9. Roy AV, Brower ME, Hayden JE: Sodium thymolphthalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 17:1093-1102, 1971.
10. Lowe FC, Trauzzi SJ: Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am 20:589-595, 1993.
11. Gutman AB: The development of the acid phosphatase test for prostatic carcinoma: The sixth Ferdinand C. Valentine memorial lecture. Bull N Y Acad Med 44:63-76, 1968.
12. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916. 1987.
13. Foti AG, Cooper JF, Herschman H, et al: Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 297:1357-1361, 1977.
14. Gutman AB, Gutman EB: An "acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 17:473-478, 1938.
15. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
16. Whitesel JA, Donohue RE, Mani JH, et al: Acid phosphatase: Its influence on the management of carcinoma of the prostate. J Urol 131:70-72, 1984.
17. Johnson DE, Prout GR, Scott WW, et al: Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology 8:123-126, 1976.
18. Paulson DF, Berry WR, Cox EB, et al: Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: Indicators of response to therapy. J Natl Cancer Inst 63:615-622, 1979.
19. Vihko P, Kontturi M, Lukkarinen O, et al: Immunoreactive prostatic acid phosphatase in prostatic cancer: Diagnosis and followup of patients. J Urol 133:979-982, 1985.
20. Reif AE, Schlesinger RM, Fish CA, et al: Acid phosphatase isozymes in cancer of the prostate. Cancer 31:689-699, 1973.
21. Stamey TA, Kabalin JN, McNeal JE, et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141:1076-1083, 1989.
22. Burnett AL, Chan DW, Brendler CB, et al: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol 148:1832-1834, 1992.
23. Jones GW, Mettlin C, Murphy GP, et al: Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990. J Am Coll Surg 180:545-554, 1995.
24. O'Dowd GJ, Veltri RW, Orozco R, et al: Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 158:687-698, 1997.
25. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991.
26. Cooperberg MR, Pasta DJ, Elkin EP, et al: The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173:1938-1942, 2005.
27. Freedland SJ, Terris MK, Csathy GS, et al: Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy gleason grade and serum prostate specific antigen. J Urol 171:2215-2220, 2004.
28. Nelson CP, Rubin MA, Strawderman M, et al: Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 59:740-746, 2002.
29. Stephenson AJ, Scardino PT, Eastham JA, et al: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98:715-717, 2006.
30. Berry WR, Laszlo J, Cox E, et al: Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44:763-775, 1979.
31. Ganem EJ: The prognostic significance of an elevated serum acid phosphatase level in advanced prostatic carcinoma. J Urol 76:179-181, 1956.
32. Moul JW, Connelly RR, Perahia B, et al: The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 159:935-940, 1998.
33. Han M, Piantadosi S, Zahurak ML, et al: Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57:707-711, 2001.
34. San Francisco IF, Olumi AF, Yoon JH, et al: Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy. BJU Int 92:924-928, 2003.
35. Dattoli M, Wallner K, True L, et al: Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer 97:979-983, 2003.
36. Dattoli M, Wallner K, True L, et al: Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Urology 69:334-337, 2007.
37. Fowler JE Jr, Braswell NT, Pandey P, et al: Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center. J Urol 153:1026-1031, 1995.
38. Zagars GK, von Eschenbach AC, Ayala AG: Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 72:1709-1725, 1993.
39. Zagars GK, Pollack A, von Eschenbach AC: Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79:1370-1380, 1997.
40. Roach M 3rd, Lu J, Pilepich MV, et al: Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol 161:864-868, 1999.
41. Wallner K, Merrick G, Blasco J, et al: Prostate Brachytherapy Made Complicated, 3rd ed. Seattle, SmartMedicine Press, 2007.
42. Oesterling JE, Martin SK, Bergstralh EJ, et al: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269:57-60, 1993.
43. Merrick GS, Butler WM, Wallner K, et al: Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer. W V Med J 101:116-119, 2005.
44. Kupelian PA, Buchsbaum JC, Elshaikh MA, et al: Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: Year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys 57:629-634, 2003.
45. Han M, Partin AW, Piantadosi S, et al: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166:416-419, 2001.
46. Shih WJ, Gross K, Mitchell B, et al: Prostate adenocarcinoma using gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements. J Natl Med Assoc 84:1049-1050, 1992.
47. Zagars GK, Pollack A, Kavadi VS, et al: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:293-306, 1995.
48. Dattoli M, Wallner K, True L, et al: Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 45:853-856, 1999.
49. Griffiths JC: Prostate-specific acid phosphatase: Re-evaluation of radioimmunoassay in diagnosing prostatic disease. Clin Chem 26:433-436, 1980.
50. Zhou R, Sause WT, Hammond EH, et al: Correlation of survival with quantitative tissue staining of prostate specific acid phosphatase in patients with prostate carcinoma by using microscopic image analysis: A preliminary report of correlative studies on RTOG protocols 75-06, 77-06, and 83-07. Int J Radiat Oncol Biol Phys 33:823-829, 1995.
51. Fang LC, Dattoli M, Wallner K, et al: Prostatic acid phosphatase predicts cancer-specific survival after palladium-103 brachytherapy for prostate cancer. Brachytherapy 6:79-80, 2007.